Anti-VEGF Receptor 3/FLT4 Antibody Picoband®

Fms-related tyrosine kinase 4, also known as FLT4 or VEGFR3, is a protein which in humans is encoded by the FLT4 gene. It is mapped to 5q35.3. This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. FLT4 has an essential role in the development of the embryonic cardiovascular system before the emergence of the lymphatic vessels. It has been found that FLT4, which provides proangiogenic signaling when expressed on endothelium, may also have antiangiogenic properties when expressed at an avascular site by nonendothelial cells. FLT4 is also regarded as a regulator of vascular network formation.

Vascular endothelial growth factor receptor 3; VEGFR-3; 2.7.10.1; Fms-like tyrosine kinase 4; FLT-4; Tyrosine-protein kinase receptor FLT4; FLT4; VEGFR3

A synthetic peptide corresponding to a sequence at the N-terminus of human VEGF Receptor 3, which shares 82.8% and 79.3% amino acid (aa) sequence identity with mouse and rat VEGF Receptor 3, respectively.

Detected in endothelial cells (at protein level) . Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney.

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3- kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr- 185', and of AKT1 at 'Ser-473'.

1. Aprelikova, O., Pajusola, K., Partanen, J., Armstrong, E., Alitalo, R., Bailey, S. K., McMahon, J., Wasmuth, J., Huebner, K., Alitalo, K. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res. 52: 746-748, 1992. 2. Galland, F., Karamysheva, A., Mattei, M.-G., Rosnet, O., Marchetto, S., Birnbaum, D. Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene. Genomics 13: 475-478, 1992.

Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.